LAYANAN INI TIDAK TERSEDIA DI WILAYAH ANDA

ABT

Kanada

Didirikan

2018 (8 Tahun)

Ditemukan

Terakhir online: Tidak ada aktivitas terbaru

Klaim perusahaan Kunjungi Situs Web

TrustScore tidak tersediaSkor belum cukup untuk menampilkan tren.

Jadilah yang pertama memberi rating dan ulasan untuk perusahaan ini.

SKOR KESELURUHAN

Lisensi

--/40

Ulasan

--/60

0 ulasan

Disediakan oleh TrustFinance

TrustScore tidak tersediaSkor belum cukup untuk menampilkan tren.

Jadilah yang pertama memberi rating dan ulasan untuk perusahaan ini.

Diatur

Direkomendasikan

(71 ulasan)

Cyprus

2009

(17 tahun)

Informasi Keamanan :

CySEC

FSCA

DFSA

Informasi Keamanan

Peringatan

Perusahaan ini saat ini Belum Terbukti.

Harap berhati-hati terhadap potensi risiko!

Lisensi

Lisensi Kelas A

Dikeluarkan oleh regulator terkenal secara global, lisensi ini memastikan perlindungan pedagang tertinggi melalui kepatuhan yang ketat, pemisahan dana, asuransi, dan audit rutin. Penyelesaian sengketa dan kepatuhan terhadap standar AML/CTF semakin meningkatkan keamanan.

Lisensi Kelas B

Diberikan oleh regulator regional yang dihormati, lisensi ini menawarkan langkah-langkah keamanan yang kuat seperti pemisahan dana, pelaporan keuangan, dan skema kompensasi. Meskipun sedikit kurang ketat daripada Tingkat 1, lisensi ini memberikan perlindungan regional yang dapat diandalkan.

Lisensi Kelas C

Dikeluarkan oleh regulator di pasar negara berkembang, lisensi ini menawarkan perlindungan dasar seperti persyaratan modal minimum dan kebijakan AML. Pengawasan kurang ketat, sehingga pedagang harus berhati-hati dan memverifikasi langkah-langkah keamanan.

Lisensi Kelas D

Dari yurisdiksi dengan pengawasan minimal, lisensi ini seringkali tidak memiliki perlindungan utama seperti pemisahan dana dan asuransi. Meskipun menarik untuk fleksibilitas operasional, lisensi ini menimbulkan risiko yang lebih tinggi bagi pedagang.

Informasi Perusahaan

Mengenal ABT

Tampilkan Lebih Banyak

Informasi Perusahaan

Mengenal ABT

ABT GROUP LTD, operating under the brand name ABT, is a financial services provider that offers online trading through the MetaTrader 5 (MT5) platform. The company provides access to leveraged trading on a variety of asset classes, including foreign exchange, global indices, precious metals, energies, and cryptocurrencies. Registered in the offshore jurisdiction of St. Vincent and the Grenadines, the firm targets a global retail trading audience.

Tampilkan Lebih Banyak

Industri

Valuta Asing Pialang RitelUTAMA
Kripto Mata uang kripto
Keuangan Nasihat Keuangan

Perangkat Lunak

Tidak ada data yang tersedia

Sepertinya bagian ini kosong. Segera kembali untuk pembaruan!

Kontak

Sosial

Ulasan

ABT Ulasan

Ulasan

Total 0

Urutkan berdasarkan

Filter

Informasi Perusahaan

Mengenal ABT

Tampilkan Lebih Banyak

Informasi Perusahaan

Mengenal ABT

Tampilkan Lebih Banyak

Industri

Valuta Asing Pialang RitelUTAMA
Kripto Mata uang kripto
Keuangan Nasihat Keuangan

Perangkat Lunak

Tidak ada data yang tersedia

Sepertinya bagian ini kosong. Segera kembali untuk pembaruan!

Kontak

Sosial

Berita

TrustFinance Badan Intelijen

Tanggal penelitian: พ.ค. 14, 2026

The website provides information that the training data is current only up to October 2023.

The content discusses Abbott Laboratories (ABT), highlighting its market challenges and strengths in medical devices. Despite facing declines in COVID-19 test sales and competition from other medical device companies, analysts maintain a consensus Buy rating with a price target of $143. The article also presents predictions for ABT's stock performance over the next few years, emphasizing the importance of innovation and new product launches for future growth.

The content discusses Abbott Laboratories (ABT), highlighting its market challenges and strengths in medical devices. Despite facing declines in COVID-19 test sales and competition from other medical device companies, analysts maintain a consensus Buy rating with a price target of $143. The article also presents predictions for ABT's stock performance over the next few years, emphasizing the importance of innovation and new product launches for future growth.

Abbott Laboratories' stock fell by 3.16% this week, closing at $86.64. The stock is trading below key moving averages, indicating strong selling pressure. Despite a decline in diagnostics business, Abbott reported growth in its vascular and nutritional segments. Analysts predict a price range of $80.30 to $92.80 for the upcoming week, with bearish momentum persisting. The overall sentiment remains cautious due to the lack of buy signals and ongoing selling pressure.

Abbott Laboratories' stock fell by 3.16% this week, closing at $86.64. The stock is trading below key moving averages, indicating strong selling pressure. Despite a decline in diagnostics business, Abbott reported growth in its vascular and nutritional segments. Analysts predict a price range of $80.30 to $92.80 for the upcoming week, with bearish momentum persisting. The overall sentiment remains cautious due to the lack of buy signals and ongoing selling pressure.

Abbott Laboratories' stock has declined by 3.05% today, trading at $83.82. The company is facing persistent selling pressure, remaining below its key moving averages, indicating strong bearish momentum. Recent developments include a dividend declaration of $0.63 per share and Q1 2026 earnings guidance of $1.12–$1.18 EPS. Analysts predict continued volatility and a potential price range of $97.00–$102.00 in the coming days, with a significant downside risk if the price falls below $97.00.

Abbott Laboratories' stock has declined by 3.05% today, trading at $83.82. The company is facing persistent selling pressure, remaining below its key moving averages, indicating strong bearish momentum. Recent developments include a dividend declaration of $0.63 per share and Q1 2026 earnings guidance of $1.12–$1.18 EPS. Analysts predict continued volatility and a potential price range of $97.00–$102.00 in the coming days, with a significant downside risk if the price falls below $97.00.

Disediakan oleh Analisis AI TrustFinance

Berita

TrustFinance Badan Intelijen

Tanggal penelitian: พ.ค. 14, 2026

The website provides information that the training data is current only up to October 2023.

The content discusses Abbott Laboratories (ABT), highlighting its market challenges and strengths in medical devices. Despite facing declines in COVID-19 test sales and competition from other medical device companies, analysts maintain a consensus Buy rating with a price target of $143. The article also presents predictions for ABT's stock performance over the next few years, emphasizing the importance of innovation and new product launches for future growth.

Abbott Laboratories' stock fell by 3.16% this week, closing at $86.64. The stock is trading below key moving averages, indicating strong selling pressure. Despite a decline in diagnostics business, Abbott reported growth in its vascular and nutritional segments. Analysts predict a price range of $80.30 to $92.80 for the upcoming week, with bearish momentum persisting. The overall sentiment remains cautious due to the lack of buy signals and ongoing selling pressure.

Abbott Laboratories' stock has declined by 3.05% today, trading at $83.82. The company is facing persistent selling pressure, remaining below its key moving averages, indicating strong bearish momentum. Recent developments include a dividend declaration of $0.63 per share and Q1 2026 earnings guidance of $1.12–$1.18 EPS. Analysts predict continued volatility and a potential price range of $97.00–$102.00 in the coming days, with a significant downside risk if the price falls below $97.00.

Disediakan oleh Analisis AI TrustFinance

ABT

Informasi Keamanan

Informasi Perusahaan

Ulasan

ABT

Informasi Keamanan

Informasi Perusahaan

Pengguna yang melihat ABT juga melihat…

IUX

XM

FXGT

Deriv

Exness

Berita

TrustFinance Badan Intelijen

The website provides information that the training data is current only up to October 2023.

Ulasan

Pengguna yang melihat ABT juga melihat…

IUX

XM

FXGT

Deriv

Exness

Berita

TrustFinance Badan Intelijen

The website provides information that the training data is current only up to October 2023.